Anti-MIF antibodies
View Patent ↗The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.
1. An isolated or purified anti-Macrophage Migration Inhibitory Factor (MIF) antibody, wherein the MIF has a molecular weight of approximately 12.5 kDa as determined by SDS PAGE, and wherein the anti-MIF antibody binds to and neutralizes a biological activity of the 12.5 kDa MIF selected from the group consisting of endotoxin lethality, cytokine-mediated toxicity, TNF-α lethality, septic shock, nitric oxide production by a macrophage, an immune response to malaria infection, an inflammatory immune response, induction of parasite killing by macrophages, and delayed type hypersensitivity response.
2. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is a polyclonal antibody.
3. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is a monoclonal antibody.
4. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is a humanized monoclonal antibody.
5. The anti-MIF antibody of claim 3 , wherein the anti-MIF antibody is a chimeric antibody.
6. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is a single chain antibody.
7. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is an Fab fragment.
8. The anti-MIF antibody of claim 1 , wherein the anti-MIF antibody is a fragment produced by an Fab expression library.
9. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is endotoxin lethality.
10. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is cytokine-mediated toxicity.
11. The anti-MIF antibody of claim 10 , wherein the cytokine-mediated toxicity is a member selected from the group consisting of endotoxin-induced toxic shock, shock, an inflammatory disease, graft-versus-host disease, an autoimmune disease, acute respiratory distress syndrome, a granulomatous disease, a chronic infection, transplant rejection, cachexia, asthma, a viral infection, a parasitic infection, malaria, and a bacterial infection.
12. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is TNF-α lethality.
13. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is septic shock.
14. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is nitric oxide production by a macrophage.
15. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is an immune response to malaria infection.
16. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is induction of parasite killing by macrophages.
17. The anti-MIF antibody of claim 1 , wherein the MIF biological activity neutralized is an inflammatory immune response.